Skip to main content
. Author manuscript; available in PMC: 2014 Jun 10.
Published in final edited form as: Exp Cell Res. 2013 Apr 3;319(10):1575–1585. doi: 10.1016/j.yexcr.2013.02.025

Fig. 3.

Fig. 3

Flow cytometry and in situ ApopTag assay for detection and determination of amounts of apoptosis in SK-N-DZ and SK-N-BE2 cells. Treatments: control (CTL), hTERT shRNA plasmid (1 μg/ml) for 12 h, miR-138 mimic (50 nM) for 12 h, 100 μM APG for 24 h, hTERT shRNA plasmid (1 μg/ml) for 12 h + 100 μM APG for 24 h, and miR-138 mimic (50 nM) for 12 h + 100 μM APG for 24 h. (A) Annexin V-FITC/PI double staining followed by flow cytometry to detect the early phase of apoptosis. (B) In situ ApopTag assay to detect the late phase of apoptosis. (C) The percentages of apoptotic cells are shown in bar diagrams based on results from three independent experiments. Difference between untreated CTL and a treatment group was considered significant at *p < 0.05 or **p < 0.01.

HHS Vulnerability Disclosure